Google
KURA 株価分析 — Kura Oncology Inc (Healthcare >> Biotechnology)
KURA に関するよくある質問
KURAのROE（自己資本利益率）は？
Kura Oncology IncのROEは-273.05%です。
KURAの配当利回りは？
Kura Oncology Incの配当利回りは0.00%です。
KURAの品質スコア（Quality Score）は？
当社のAIはKURAの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
KURAは今が買い時ですか？
当社AIのタイミングスコアは100点中55点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
KURAはどのセクターに属しますか？
Kura Oncology IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
KURA AI Analysis Summary
Our AI summary for KURA: Kura Oncology Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -273.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 9.47
Price
0.28
(3.05%)
Day Change
|
|
|---|
KURA, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.47 |
| PBV / Sector |
7.56 / 44,022.72
|
| Earning Per Share | -3.42 |
| PE / Sector |
N/A / 19.17
|
| PEG or PE/Growth / Sector |
N/A / 1.24
|
| Average 1M Daily Value |
12.95 M
GREAT
|
| Average 1W Daily Value |
11.95 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:27 |
| Symbol | KURA |
| Name | KURA ONCOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 88.77 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 815.84 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 4930 Directors Place, San Diego, CA, United States, 92121
Phone: 858 500 8800
Website: https://kuraoncology.com
Employees: 260
Sector: Healthcare >> Biotechnology
Description: Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
